Efficacy and Safety of Abrocitinib in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN study
Lawrence Eichenfield
(1)
,
Carsten Flohr
(2)
,
Robert Sidbury
(3)
,
Zsuzsanna Szalai
(4)
,
Ryszard Galus
(5)
,
Zhirong Yao
(6)
,
Hidetoshi Takahashi
(7)
,
Sébastien Barbarot
(8)
,
Claire Feeney
(9)
,
Fan Zhang
(10)
,
Marco Dibonaventura
(10)
,
Ricardo Rojo
(10)
,
Hernan Valdez
(10)
,
Gary Chan
(10)
1
UC San Diego -
University of California [San Diego]
2 King‘s College London
3 Seattle Children’s Hospital
4 Pál Heim Children's Hospital = Heim Pál Gyermekkórház [Budapest]
5 Medical University of Warsaw - Poland
6 Shanghai Jiao Tong University School of Medicine
7 Takagi Dermatological Clinic
8 PhAN - Physiopathologie des Adaptations Nutritionnelles
9 Pfizer Ltd
10 Pfizer Inc
2 King‘s College London
3 Seattle Children’s Hospital
4 Pál Heim Children's Hospital = Heim Pál Gyermekkórház [Budapest]
5 Medical University of Warsaw - Poland
6 Shanghai Jiao Tong University School of Medicine
7 Takagi Dermatological Clinic
8 PhAN - Physiopathologie des Adaptations Nutritionnelles
9 Pfizer Ltd
10 Pfizer Inc